Global Polymerase Chain Reaction (PCR) and Digital PCR Market Size, Share, Trends and Forecast 2026-2033

Global Polymerase Chain Reaction (PCR) and Digital PCR Market Size, Share, Trends and Forecast 2026-2033

Market Forecast Snapshot, 2025-2033

The market, stated plainly

The global polymerase chain reaction and digital PCR market was valued at USD 10.42 billion in 2025 and is forecast to reach USD 15.40 billion by 2033. Eight periods of compounding gives a 1.4779x expansion and an implied compound annual growth rate of 5.0042%, stated throughout as 5.00%. Incremental revenue across the window is USD 4.98 billion.

The thesis: the enzyme is not the product

PCR is the most successful diagnostic technology ever deployed and it has almost no pricing power left in it. The chemistry was solved before most of the current participants were founded, the patents that mattered expired, and the cost of amplifying a target has fallen far enough that amplification is no longer what a customer is buying. What a customer buys now is a cleared intended use on a validated menu, delivered on a box that is already installed, and paid for by a third party at a scheduled price.

That reframing changes what the forecast is measuring. If PCR were a technology market, its growth would track the technology's capability, and the last three years would have been a boom. Instead, over 2025, the same chemistry produced +4% CER at Roche's Molecular Lab, -1.2% organic at Abbott's Molecular Diagnostics, and a 9% CER decline in QIAGEN's PCR product group in the fourth quarter. Three participants, one chemistry, three directions. The variable that separated them was not the polymerase. It was which menus they had cleared, which geographies they were selling into, and whether their revenue sat inside a closed cartridge system where the customer cannot substitute the reagent.

The report therefore treats the market as two businesses with a shared chemistry. Closed cartridge PCR – the syndromic and pathogen menus sold on Cepheid, bioMérieux and Roche platforms – is a menu business with recurring consumable revenue and a cleared-indication moat. Open qPCR – instruments and master mixes sold to laboratories that buy or build their own assays – is a reagent commodity sold into capital-constrained accounts. They grow at different rates, they deflate differently, and in 2025 they moved in opposite directions.

Digital PCR sits outside both, and it is the only part of the category where the product is not a result but a number. A digital PCR instrument returns an absolute copy count without a standard curve, which is a different claim from a cycle threshold, and it is a claim that regulated buyers will pay a premium for. That is why the smallest technology in this report carries the highest growth rate and the only genuinely contested competitive field.

Three findings that carry the forecast

One. The disclosed growth spread of 2025 is a menu and geography story, and it should not be averaged into a single run-rate. Roche's Molecular Lab customer area reached CHF 2,527 million, up 4% at constant exchange rates and equal to USD 3,048 million at the 2025 average rate, while the Diagnostics Division overall grew 2% and Asia-Pacific fell 12% on Chinese pricing reform. Abbott's Molecular Diagnostics line reached USD 517 million, down 1.2% on an organic basis. Roche's molecular franchise is therefore roughly 5.9 times Abbott's and growing four points faster in the same year. The difference is not analytical performance. It is that Roche's molecular revenue is weighted towards viral load monitoring, donor screening and sexual health – contracted, guideline-driven, non-discretionary testing – while a larger share of Abbott's molecular base sits in respiratory and point-of-care channels where volume follows the season.

Two. Digital PCR is 6.33% of this market and contributes 0.95 points of the 5.00%. The arithmetic is not rhetorical. On a base of USD 10.42 billion with digital PCR at USD 0.66 billion, a 15% digital PCR growth rate adds 0.95 percentage points, and qPCR at approximately 4.3% adds 4.06 points, for 5.01 points in total. Anyone forecasting a high-single-digit rate for this category is forecasting a digital PCR outcome for a market that is 93.67% qPCR. QIAGEN, the most transparent participant in the digital segment, put its own 2025 digital PCR revenue at USD 89 million against a target of USD 100 million in 2026 and USD 250 million by 2028, on an installed base that passed 3,200 cumulative placements with more than 500 systems placed in 2025.

Three. 2025 is the first clean base year since 2019, and it is a trough rather than a trend. Three drags were active at once and all three are policy or funding events rather than commercial ones. COVID-19 testing revenue left the base: Abbott's COVID-19 testing-related sales fell from USD 747 million to USD 297 million, a decline of 60.24%, and 2025 is the last year in which a COVID comparison of any size remains inside a reported growth rate. China repriced molecular testing: Roche's Asia-Pacific diagnostics revenue fell 12% at constant exchange rates to CHF 3,386 million, and Abbott called out volume-based procurement as a constraint on Core Laboratory growth. Academic funding constrained instrument capex: Bio-Rad's Life Science segment declined 1.3% at constant exchange rates to USD 1,021.1 million on constrained academic and biotech funding, and QIAGEN disclosed that digital PCR instrument placements ran below its own expectations for the same reason while consumables grew at a double-digit rate.

A 5.00% forecast on top of a base compressed by three simultaneous transient drags is not an aggressive number. It requires those drags to stop dragging, and it does not require any of them to reverse.

What is inside the perimeter, and why published figures disagree

This report measures PCR instruments and reagents across clinical diagnostics, life science research and applied testing. It excludes services (validation, laboratory-developed assay development, sequencing services), software and bioinformatics, and sample-preparation-only consumables such as extraction kits that are not PCR reagents. It excludes all residual COVID-19 assay revenue from the 2025 base, not merely the decline in it, so the base year is what the market sells in the absence of an emergency declaration. And it excludes antigen, serology and isothermal testing, which are separate products with separate economics even where they compete for the same clinical question.

That perimeter has to be stated loudly, because the published figures for this category are not comparable with each other. The clearest demonstration comes from two primary sources read together. QIAGEN's own investor material puts the 2025 qPCR total addressable market at approximately USD 2.7 billion, with digital PCR at approximately USD 0.6 billion and NGS consumables at approximately USD 1.9 billion. In the same year, Roche's Molecular Lab customer area alone reported CHF 2,527 million, or USD 3,048 million, the overwhelming majority of which is PCR-based testing on closed and open platforms.

Both figures are honestly reported and they cannot both describe the same market. The reconciliation is definitional rather than arithmetic: QIAGEN's addressable market is the market QIAGEN can sell into, which is open qPCR chemistry and consumables, and it structurally excludes closed cartridge systems where the reagent is proprietary to the platform. Those closed systems are precisely where Roche, Cepheid and bioMérieux earn their molecular revenue. A vendor's addressable market is a sales instrument, not a measurement, and a report that adopts one as the size of the category will understate it by the entire installed base of its competitors. It will also, and more damagingly, predict that market's future using a growth rate that belongs to a different business.

How the 2025 base was constructed

Because no participant discloses PCR as a revenue line, the base is a stated construction rather than an inherited figure. Four disclosed pools carry an explicit attributable split, six categories are estimated from disclosed segment scale, and a named residual reconciles the total to USD 10,420 million.

Two features of that table matter more than any individual row. First, the reconciling residual is USD 705 million, or 6.8% of the base, which is small for a category with this many unlisted regional suppliers and indicates that the disclosed pools genuinely cover most of the market. Second, the Roche conversion is the largest single use of judgement in the table: at CHF 2,527 million and an 80% PCR-attributable split, it contributes 23.4% of the base on its own, and a 70% or 90% split would move the total by USD 300 million in either direction. The split reflects the composition Roche itself describes for that customer area – pathogen detection and monitoring, donor screening, sexual health and genomics – where genomic tumour profiling is the non-PCR component.

Digital PCR is carried inside that total at USD 0.66 billion, or 6.33%. That is set against QIAGEN's USD 0.6 billion addressable estimate and implies a QIAcuity share of roughly 14.8% on a USD 89 million revenue line. The two are consistent, and the consistency is worth noting because it is unusual in this category: the supplier's own addressable estimate and an independent bottom-up construction land within 10% of each other, which is not true of the qPCR figure above.

How to read the chapters that follow

The competitive landscape chapter separates the closed cartridge layer from the open qPCR layer and shows why the same chemistry produced opposite growth rates. The value chain chapter locates the bottleneck at validation rather than amplification, and prices the difference. The technology chapter explains precisely which claims digital PCR can make that qPCR cannot, and where the multiplex ceiling stops it. The investment chapter reads 2025's disclosed capital decisions as a shift from capacity to menu. The risk chapter states eight transmission channels, including the pair that arrives together. The regulatory chapter shows that for PCR the binding rule is the cleared intended use, not the analytical performance, and that the laboratory-developed test framework sets the American price ceiling.

Table of Contents

Table of Contents

1. Market Forecast Snapshot, 2025-2033
2. The thesis: the enzyme is not the product
3. Three findings that carry the forecast
4. What is inside the perimeter, and why published figures disagree
5. How the 2025 base was constructed
6. Competitive Landscape
7. Value Chain and Margin Structure
8. Technology Insight: qPCR, Digital PCR and the Multiplex Ceiling
9. Investment and Capital Formation
10. Market Risk Assessment
11. Regulatory and Policy Environment

Competitive Landscape

Competitive Landscape

This market has nine participants of tier-one scale and no meaningful concentration at the level of the technology. What is concentrated is the menu, and the menu is where the competitive positions actually sit.

The two layers, and why they behave differently

Closed cartridge systems are the first layer: a proprietary cartridge run on a proprietary instrument, with the reagent, the consumable and the software supplied by one company, sold against a cleared indication. Cepheid’s GeneXpert, bioMérieux’s BIOFIRE and SPOTFIRE, and Roche’s cobas platforms are the reference products. The economics of this layer are a razor-and-blade: the instrument is placed, often at a price that does not recover its cost, and the cartridge annuity follows for the life of the placement. The moat is not the hardware. It is that the customer cannot substitute the reagent, cannot build the cartridge in-house, and cannot switch platform without abandoning a validated workflow and a trained staff.

Open qPCR is the second layer: an instrument and a master mix sold to a laboratory that buys primers and probes from a third party or designs its own assays. Thermo Fisher, Bio-Rad, QIAGEN and Agilent compete here. The customer can substitute the reagent brand without changing the instrument, which makes the master mix a commodity with a price elasticity that the closed layer does not have. The moat in this layer is instrument installed base and the switching cost of validated laboratory protocols, both of which are real and both of which are weaker than a cartridge.

These two layers grew in opposite directions in 2025, and that is the most important empirical fact in this report. Roche’s Molecular Lab customer area – a closed-platform business weighted towards viral load, donor screening and sexual health – reached CHF 2,527 million, up 4% at constant exchange rates, which is USD 3,048 million at the 2025 average rate of 1.2062. Abbott’s Molecular Diagnostics line reached USD 517 million, down 1.2% on an organic basis. Roche’s molecular franchise is 5.9 times the size of Abbott’s and grew five points faster in the same twelve months, on the same underlying chemistry.

The comparison is not a comment on either company’s products. It is a comment on revenue composition. Roche’s molecular base is dominated by testing that a guideline requires and a payer covers regardless of season: HIV and hepatitis viral load, blood donor screening, high-risk HPV genotyping. Abbott’s molecular base carries a larger respiratory and point-of-care component, and respiratory molecular volume follows the epidemiology of the winter. In a category where the chemistry is common, the mix is the strategy.

Digital PCR: the only contested field

Digital PCR is small, fast-growing, and the only part of this market where the competitive order is still being decided. QIAGEN estimates the segment at approximately USD 0.6 billion in 2025, growing above 15% a year, against approximately USD 2.7 billion for qPCR and USD 1.9 billion for NGS consumables on the same definitional basis.

The disclosed positions are unusually informative for a segment this size. QIAGEN’s QIAcuity reached USD 89 million of net sales in 2025 against a USD 100 million target for 2026, on more than 3,200 cumulative placements since its 2020 launch, including more than 500 systems placed during 2025 and more than 100 in the fourth quarter alone. The installed base has compounded at roughly 75% a year and revenue at roughly 55% a year across 2020 to 2025. QIAGEN states that QIAcuity took more than 12% of the digital PCR market within four years, and the arithmetic supports a higher figure: USD 89 million against a USD 600 million segment is 14.8%.

Bio-Rad holds the largest established digital PCR installed base through its Droplet Digital franchise and, in 2025, bought the nanoplate challenger rather than compete with it: the acquisition of Stilla Technologies closed on 7 July 2025 and was integrated during the year, with the company reporting satisfaction with early adoption of the expanded portfolio. Thermo Fisher entered with the QuantStudio Absolute Q in 2021, and Roche launched the Digital LightCycler in 15 countries in 2022. Four credible platforms, one leader by installed base, one challenger growing fastest.

The competitive question in digital PCR is not who has the best partitioning method. It is whether the segment’s growth is a market phenomenon or a share phenomenon, and the disclosed targets answer it. If the segment compounds at 15% from USD 600 million, it reaches USD 912 million by 2028. QIAGEN’s USD 250 million target for that year would then represent 27.4% of the whole segment – roughly double the share its current revenue implies. QIAGEN’s own digital PCR plan is a share-gain plan, and it is being executed in a segment where the largest incumbent has just bought the second-largest nanoplate platform. This is the one part of the PCR category where a competitive position can still be lost.

What 2025 disclosed about the rest of the field

Danaher does not disclose Cepheid revenue, but it discloses enough to size the seasonality: Cepheid respiratory revenue was approximately USD 500 million in the fourth quarter of 2025 alone, against Diagnostics core growth of 1.5% for the full year. Cepheid also received FDA clearance for its Xpert GI Panel, a multiplex PCR test detecting 11 gastrointestinal pathogens from a single sample – a menu extension, which is the competitive move this layer rewards.

Hologic’s molecular diagnostics revenue grew 0.4% at constant currency in the fourth fiscal quarter, or 4.5% excluding COVID-19 and related revenue, driven by BV CV/TV and Panther Fusion assays. That gap between the reported and the underlying rate is the cleanest single illustration in this report of what a COVID comparison still does to a molecular growth rate. Hologic also agreed in October 2025 to be acquired by funds managed by Blackstone and TPG at up to USD 79 per share, which removes one independent molecular franchise from the listed field.

QIAGEN’s PCR product group declined 9% at constant exchange rates in the fourth quarter, even as QIAcuity consumables grew at a double-digit rate and the group’s adjusted operating margin improved 80 basis points to 29.5% for the year. That combination – declining PCR revenue, improving margin – is the signature of a portfolio being re-mixed towards higher-value products and away from commoditised consumables, and it is the correct strategic response to this market’s structure.

Bio-Rad reported Life Science net sales of USD 1,021.1 million, down 1.3% at constant exchange rates, attributing the decline to the constrained academic research and biotech funding environment. This is the open-qPCR layer’s binding constraint in one line: the reagent and instrument demand that comes from grant-funded laboratories is a function of grant budgets, and grant budgets did not grow.

Thermo Fisher reported Life Sciences Solutions revenue of USD 10,374 million at a 36.3% segment margin, the highest margin disclosed by any participant in this market and the clearest evidence of where the value in the chain sits. The qPCR franchise is a small part of that segment, but it sits inside the segment with the best economics, which is not a coincidence: reagents and consumables carry the margin, instruments rarely do.

The Chinese layer and the price floor

Below the nine tier-one participants sits a layer of Chinese suppliers – Sansure, DaAn Gene, Maccura, BGI and others – that scaled on COVID-19 testing and now sell PCR reagents into a domestic market repriced by volume-based procurement. This layer is material in volume, largely invisible in disclosed revenue, and decisive for price. Its export pricing sets the floor for open PCR consumables in every emerging market, and its domestic pricing is the mechanism by which Roche’s Asia-Pacific diagnostics revenue fell 12% at constant exchange rates in 2025.

Any statement that this market lacks large participants should be treated as an error, and any share table that omits the closed cartridge layer should be treated as a share table of a different market. This report describes the structure as moderately consolidated at the platform layer and fragmented at the reagent layer, with high competitive intensity throughout, and it counts nine participants of tier-one scale.

What cannot be known from filings

Three things should be listed as unknown rather than estimated. No participant discloses PCR as a revenue line, so every attributable split in this report is a construction and is labelled as one. Cepheid’s USD 500 million respiratory figure is a quarter, not a year, and Danaher provides no annual molecular line. And installed-base counts are disclosed selectively – QIAGEN by quarter, Bio-Rad by franchise, nobody else at all – so a cross-company placement league table cannot be built from primary sources.

Value Chain

Value Chain and Margin Structure

The PCR value chain has seven stages and one bottleneck. The bottleneck is not where the technology is hardest, which is why the margin distribution in this market is persistently misread.

Stage one: enzymes and master mixes

The thermostable polymerase, the reverse transcriptase, the nucleotides and the buffer chemistry. This is the highest-margin stage in the chain and it is concentrated in a small number of suppliers: Thermo Fisher, Roche’s CustomBiotech business, and New England Biolabs among them. Thermo Fisher’s Life Sciences Solutions segment, which contains this business, reported USD 10,374 million of revenue at a 36.3% segment margin in 2025 – the best margin disclosed by any participant covered in this report. The intellectual property that once protected this stage has largely expired, but the manufacturing consistency and the quality documentation have not, and a regulated laboratory cannot switch enzyme supplier without revalidating its assay.

Stage two: oligonucleotides, primers and probes

Synthetic DNA sold to laboratories that design their own assays, and to manufacturers that embed it in kits. This stage is competitive, technically mature and priced on synthesis scale. Consolidation has been steady: the larger life-science groups have bought synthesis capacity to secure supply for their own menus rather than to earn a margin from selling oligos.

Stage three: plastics and consumables

Thin-wall plates, strip tubes, sealing films, and – in digital PCR – the nanoplate or the droplet-generation cartridge. This is the least defensible stage in the chain and the one most exposed to the Chinese cost curve, with the exception of proprietary digital PCR consumables, which are locked to their platform and therefore carry platform margins rather than plastics margins.

Stage four: instruments

Thermocyclers, optical systems, fluidics and the software that runs them. Instruments are the stage where the least value is captured and the most capital is deployed, and the reason is competitive: a qPCR instrument is a durable good with a ten-year life, sold into an account that already owns one. The economics are those of a customer acquisition cost, and the participants treat them that way. QIAGEN placed more than 500 QIAcuity systems in 2025 and disclosed that instrument placements ran below its own expectations because academic capital budgets were constrained – a statement about a discretionary purchase, not about demand for the assays those instruments would run.

This is the single most important structural feature of the market and it is worth stating plainly: the instrument is not the product. It is the mechanism by which a company acquires the right to sell consumables for a decade. A company that wins an instrument placement at a loss and loses the consumable annuity has lost money twice.

Stage five: validation and the cleared menu

This is the bottleneck, and it is where the margin actually accumulates. Converting an assay into a product that a laboratory can report to a clinician requires analytical validation, clinical evidence, a regulatory submission and, in most reimbursed markets, a coverage determination. The cost of that work is largely fixed per assay and it is recovered across the installed base, which means the return on validation rises with the size of the installed base and falls for anyone who does not have one.

The disclosed numbers show what a validated menu is worth. QIAGEN reports more than 2,700 validated QIAcuity assays and more than 1,100 publications referencing the platform in 2025. Those two figures are the same asset described twice: a publication is a laboratory demonstrating that an assay works, and a validated catalogue entry is a customer who does not have to develop one. In a market where the chemistry is a commodity, the catalogue is the product.

The corollary is that validation cost is a barrier to entry that has nothing to do with capability. A smaller competitor can build a thermocycler. It cannot cheaply assemble a catalogue of cleared assays across twenty clinical indications in thirty jurisdictions, and it cannot amortise that cost over a small installed base. This is why the tier-one set has been stable for a decade while the underlying technology has changed twice.

Stage six: distribution, service and tender access

In reimbursed markets this is a sales and service function. Outside them it is the whole business: ministries and donor-funded programmes buy through tender, and access requires registration files and, for programme procurement, prequalification. The cost of maintaining those registrations is fixed and the barrier it creates is administrative rather than technical, which favours incumbents in exactly the geographies where volume growth is fastest.

Stage seven: the laboratory

The customer, and in the United States a potential competitor. Because the laboratory-developed test framework survived its 2025 legal challenge, a laboratory can build its own assay rather than buy one, which caps what a supplier can charge for any assay a competent laboratory could reproduce. The price of a PCR test in America is therefore set at the lower of what the supplier charges and what the laboratory’s own cost would be – a ceiling that no amount of product improvement removes.

Where the margin actually sits, and where it is moving

QIAGEN’s 2025 results contain the cleanest available demonstration of the margin structure. The company’s PCR product group declined 9% at constant exchange rates in the fourth quarter, while its adjusted operating margin rose 80 basis points to 29.5% for the full year. Revenue fell and margin rose, which is only possible if the mix moved towards higher-value products: digital PCR consumables growing at a double-digit rate, and lower-margin commoditised PCR consumables shrinking.

That pattern defines the direction of value migration in this market. Value is moving away from amplification – which is now cheap, fast and undifferentiated – and towards two things: the cleared menu that tells a clinician what a result means, and the absolute quantification that digital PCR provides and qPCR cannot. Everything else in the chain is being repriced towards its cost of production, and in China it is being repriced below it.

The consequence for the forecast is direct. A market whose value is migrating towards menus and away from reagents grows at the rate at which menus expand, not at the rate at which testing volume expands. Those are different numbers, and the second is larger. Global PCR test volume is growing faster than global PCR revenue, and it will continue to do so for as long as volume-based procurement and multiplex substitution are pushing price per reportable result down. That gap between volume growth and revenue growth is the defining feature of this market, and it is why a 5.00% forecast is not a pessimistic reading of a growing category – it is the arithmetic of a category growing in units and deflating in price.

Investment Activity

Investment and Capital Formation

Capital in this market is not being deployed to make more PCR. It is being deployed to own the menu, and 2025’s disclosed transactions say so with unusual consistency.

The defining transaction: Bio-Rad buys the challenger

Bio-Rad completed the acquisition of Stilla Technologies, a digital PCR developer, on 7 July 2025 and integrated it during the year, reporting satisfaction with early market adoption of the expanded Droplet Digital portfolio. Read as a technology purchase, this makes little sense: Bio-Rad already owned the largest droplet digital PCR franchise in the world, and Stilla’s platform is a nanoplate system, which is a different partitioning method competing with Bio-Rad’s own.

Read as a defensive acquisition, it makes complete sense. Nanoplate and chip-based digital PCR had been taking the majority of new placements because it requires fewer hands-on steps and suits staff already trained on qPCR – a workflow advantage that droplet generation does not have. Rather than defend a workflow position against a format shift, Bio-Rad bought the format. The purchase price was not disclosed in a form that isolates the digital PCR business, and this report does not estimate it. What is disclosed is the strategic logic: in a segment compounding above 15% a year, the leader bought the fastest-improving challenger rather than out-engineer it.

The consequence for the competitive order is that the two largest nanoplate challengers – QIAGEN’s QIAcuity and Stilla’s platform – now sit on opposite sides of a single transaction, and QIAGEN’s disclosed ambition of USD 250 million of digital PCR revenue by 2028 has to be earned against an incumbent that has consolidated the alternative.

Placements are the capital programme

QIAGEN placed more than 500 QIAcuity systems in 2025, including more than 100 in the fourth quarter, and disclosed that annual instrument placements ran below its own expectations because academic capital budgets were constrained. That is a statement about a discretionary capital purchase by a grant-funded customer, and it is the clearest investment signal in the market: the constraint on digital PCR adoption in 2025 was not demand for the assays but the willingness of universities to spend capital.

The economics of that placement matter for how the investment should be read. An instrument placed in 2025 generates consumable revenue for the remainder of its service life, which is why QIAGEN can report consumables growing at a double-digit rate while instrument placements disappoint. A deferral of capex in 2025 is therefore not lost revenue; it is revenue that arrives later, with a smaller installed base behind it. The company’s own disclosure – that it might see a slight delay against the 2028 target because of the spending environment, while continuing to place over 100 systems a quarter – is the honest version of that trade-off.

Menu capex, not capacity capex

Danaher’s FDA clearance of the Xpert GI Panel, a multiplex PCR test detecting 11 gastrointestinal pathogens from a single sample, is an investment in a cleared indication rather than in manufacturing capacity. That is where capital is going across this market: the instrument platforms are built, the manufacturing footprint was expanded during the pandemic and is now underused, and the binding constraint on revenue is the number of indications a company is allowed to sell against. A cleared menu extension is the highest-return capital a PCR business can deploy.

The same logic explains the absence of greenfield capacity announcements across the tier-one set. Manufacturing capacity for PCR consumables was built at pandemic scale and has not been fully absorbed: Abbott’s rapid diagnostics revenue fell 18.1% to USD 2,454 million in 2025 and its COVID-19 testing revenue fell to USD 297 million from USD 747 million. An industry with surplus consumable capacity and a clearing constraint on indications does not build plants. It files submissions.

Ownership change and the listed field

Hologic agreed in October 2025 to be acquired by funds managed by Blackstone and TPG in a transaction valued at up to USD 79 per share. For a molecular diagnostics franchise growing at 0.4% at constant currency on a reported basis and 4.5% excluding COVID-19 revenue, a take-private at that value is a statement about the public market’s view of molecular PCR growth rather than about the asset’s quality. The practical effect on the competitive landscape is that one independent tier-one molecular franchise leaves the listed comparison set, and its capital allocation decisions stop being observable.

Consolidation in this market is therefore running in two directions at once: platform companies buying format positions, and financial buyers taking mature franchises private. What is not being acquired is undifferentiated reagent capacity, because reagent capacity is the one thing in this chain that is not scarce.

Adjacent to the core, QIAGEN completed the acquisition of Parse Biosciences in December 2025, extending its sample technologies into single-cell analysis. That is not a PCR transaction and it is not counted in this report’s perimeter, but it indicates where the strategic adjacency is being sought: not towards more amplification, but towards the sample and the data layer that surround it.

The guidance that constrains the forecast

Two disclosed forward commitments bracket the 5.00% forecast from below.

Bio-Rad guided 2026 constant-currency revenue growth of approximately 0.5% to 1.5%, after a 2025 in which Life Science declined 1.3% at constant exchange rates and total revenue was flat on the same basis. That is a company with significant PCR exposure telling the market it expects near-zero growth in the coming year.

QIAGEN guided 2026 to net sales growth of at least 5% at constant exchange rates, with its growth pillars contributing approximately USD 1.64 billion at roughly 9% CER, and reiterated a USD 250 million digital PCR target for 2028 while acknowledging a possible slight delay.

Those two statements are not contradictory; they describe different mixes within the same market. But together they set the boundary of what a defensible forecast can claim. A 5.00% market rate for 2026 to 2033 sits above Bio-Rad’s near-term guidance and at QIAGEN’s two-year ambition, which is exactly where a market aggregate belongs if the drags identified in this report fade rather than persist. If they persist, the aggregate is too high, and the sensitivity in the risk chapter shows what that costs.

Capital intensity

Capital intensity in this market is high at the instrument and manufacturing layers and low at the assay layer. That asymmetry determines who can enter and where returns accrue. Building a thermocycler platform requires tooling, optics supply, software and a global service organisation. Building an assay on someone else’s platform requires a laboratory and a validation budget. The first is a barrier; the second is a business model, and it is why the number of assay developers on the leading platforms grows while the number of platform owners does not.

Technology & Innovation

Technology Insight: qPCR, Digital PCR and the Multiplex Ceiling

The distinction between real-time PCR and digital PCR is often described as a difference in precision. It is more usefully described as a difference in what the instrument is asked to produce: a comparison or a count. That difference determines which applications digital PCR can take from qPCR, which it cannot, and why its growth rate does not transfer to the rest of the market.

How real-time PCR produces an answer

Real-time PCR amplifies a target in a single reaction volume and measures fluorescence at every cycle. The cycle at which the signal crosses a threshold – the Ct value – is inversely related to the starting quantity of target. Because the relationship is logarithmic and the efficiency of each reaction varies slightly with the sample matrix, the Ct value is a relative measurement: to convert it into a copy number, the laboratory must run a standard curve of known concentrations alongside the samples, on the same plate, under the same conditions. That standard curve is the source of most of the between-laboratory variance in qPCR results, and it is the reason two laboratories running the same assay on the same sample can report materially different viral loads.

The strengths of the format are speed, cost per well, and multiplex ceiling. A qPCR plate reads in under two hours and, on the leading syndromic platforms, a single reaction can carry twenty or more targets distinguished by fluorophore and melting temperature. That multiplex capability is what made the syndromic respiratory and gastrointestinal panels commercially possible, and it is the capability digital PCR does not have.

How digital PCR produces a count

Digital PCR partitions a single sample into thousands of independent micro-reactions, runs the amplification to endpoint in every one, and counts how many partitions contained a target. Because the partitions are independent and the amplification runs to saturation, the fraction of positive partitions is converted into an absolute concentration by a Poisson correction. No standard curve is required, and the result is expressed as copies per microlitre rather than as a relative cycle threshold.

Two partitioning methods compete. Droplet digital PCR, commercialised at scale by Bio-Rad, emulsifies the sample into tens of thousands of nanolitre droplets. Nanoplate and chip digital PCR – QIAGEN’s QIAcuity, Thermo Fisher’s QuantStudio Absolute Q, Roche’s Digital LightCycler – partitions the sample into fixed physical chambers on a consumable. The physical difference is real and it has commercial consequences: nanoplate systems require fewer hands-on steps, accept standard laboratory plastics workflows and are easier for staff trained on qPCR, which is why they have been taking the majority of new placements even where droplet systems hold the larger installed base.

What the disclosed specifications actually mean

QIAGEN’s published capabilities for QIAcuity are the most specific set of specifications disclosed by any participant in this market: up to 12 targets measured in a single reaction, a run time of under two hours, and throughput of more than 1,500 samples per day on the highest-throughput configuration. Those three numbers define the segment’s competitive envelope precisely.

Twelve targets is a strong multiplex performance for digital PCR and it is still below the twenty-plus targets that syndromic qPCR panels achieve. That gap is the multiplex ceiling, and it is structural rather than temporary: partitioning a sample into thousands of reactions divides the target molecules across them, so the number of distinguishable targets per partition is limited by the molecules present, not only by the chemistry. Digital PCR is therefore not a candidate to replace syndromic respiratory panels, and any forecast that assumes it will is wrong about the physics.

Under two hours and 1,500 samples a day, on the other hand, is competitive with qPCR for high-volume batch work. This is the segment where digital PCR takes share: applications that need a precise copy number at high throughput and do not need twenty-plex respiratory coverage.

Where digital PCR wins, and why those applications are growing

Four application families account for most digital PCR demand, and each is growing for a reason that is independent of the platform’s price.

Low-copy-number detection and monitoring. Minimal residual disease in leukaemia, JAK2 V617F allele burden in myeloproliferative neoplasms, BCR-ABL transcript monitoring. In each, the clinical decision depends on a change in a variant allele fraction of a fraction of a percent, which is below the reliable resolution of a standard curve. A count does not need a standard curve, and the precision at low copy number is the product.

Liquid biopsy and circulating tumour DNA. The same argument in oncology: the signal is rare, the sample is small, and the difference between 0.1% and 0.3% variant allele fraction can be the difference between continuing and changing therapy.

Copy number variation and gene expression. Absolute transcript counts remove the normalisation problem that makes qPCR gene-expression results difficult to compare across laboratories. QIAGEN explicitly identifies gene expression as a primary use case alongside cell and gene therapy, which is the strategic reason its assay portfolio grew more than 75% in 2025.

Cell and gene therapy quality control. Vector copy number, residual host DNA and vector titration are release-testing measurements that must be reproducible across sites and comparable to a specification. An absolute count is a more defensible regulatory submission than a relative one, which is why this is the fastest-growing application family in the segment even though it is tiny in absolute revenue.

What digital PCR cannot take, and what that means for the forecast

Three limits matter for the forecast.

The multiplex ceiling. Twelve targets against twenty-plus. Syndromic panels – the fastest-growing part of clinical PCR demand – stay on qPCR.

Cost per reportable result. A digital PCR consumable is more expensive per sample than a qPCR well, and the instrument is more expensive per unit of throughput. Where a laboratory needs a yes-or-no answer at the lowest possible cost – screening, donor testing, high-volume infectious disease – qPCR wins on unit economics and will continue to.

The installed base. There are hundreds of thousands of qPCR instruments in service worldwide and more than 3,200 QIAcuity systems. Even at 15% annual growth in placements, digital PCR does not become the volume platform in this forecast window. It becomes the platform for the applications where an absolute count is worth a premium, which is a smaller market with a better margin.

The unaddressed technical constraint: sample preparation

The stage of the workflow that limits PCR performance is upstream of the amplification. Inhibition, low sample input, inefficient lysis and degraded nucleic acid determine the sensitivity of a result far more than the polymerase does, and the same constraint bites harder in digital PCR because partitioning a dilute sample into thousands of reactions concentrates the effect of molecule loss.

This is why sample-preparation-only consumables are excluded from this report’s perimeter but cannot be excluded from any serious discussion of its future. The companies that improve the front end of the workflow increase the value of every reagent sold downstream, and the companies that own the front end have a structural advantage in selling the rest. QIAGEN’s own framing of its position – sample technologies as the entry point to the workflow – is the correct strategic reading of where the technical constraint sits.

The missing standard

There is no common data format across PCR platforms. A Ct value from one instrument is not directly comparable to a Ct value from another, and the standard curves that would make them comparable are laboratory-specific. That fragmentation is an annoyance in research and a genuine obstacle in regulated testing, where a result must be defensible across sites, over time, and to an inspector.

Absolute quantification is a partial answer to that problem, which is the strongest technical argument for digital PCR adoption in regulated environments and the reason its stake in cell and gene therapy quality control matters beyond its current revenue. A count travels better than a threshold cycle. That is a durable advantage, and it is the reason this report forecasts digital PCR at approximately 15% annual growth while the market it sits inside grows at 5.00%.

Market Risk

Market Risk Assessment

The 5.00% forecast survives a normal range of outcomes and fails a specific combination. The eight risks below are ordered by how directly each attacks the revenue line, with the transmission channel stated in each case rather than left implied.

1. China pricing reform and volume-based procurement

This is the most material single geographic risk in the market. Roche’s Asia-Pacific diagnostics revenue fell 12% at constant exchange rates to CHF 3,386 million in 2025, in a year when the group’s diagnostics division grew 2% and North America grew 9%. Abbott identified volume-based procurement as a constraint on Core Laboratory growth. Transmission channel: procurement resets the price per test rather than the volume of testing, so revenue falls while the number of tests performed is unchanged or higher. PCR is the most exposed modality in the market to this mechanism because it is the highest-volume molecular line, and the risk is not cyclical – it is an administrative repricing with no natural floor beyond the supplier’s cost of goods. A forecast that treats 2025’s China decline as a one-year event is assuming a policy reversal that no disclosed source supports.

2. Constrained academic and biotech funding

Bio-Rad attributed its 1.3% constant-currency decline in Life Science revenue to USD 1,021.1 million directly to the constrained academic research and biotech funding environment. QIAGEN disclosed that digital PCR instrument placements ran below its own expectations for the same reason, while consumables grew at a double-digit rate. Transmission channel: the laboratory that would have bought an instrument defers the purchase and continues running its existing platform, which removes instrument revenue immediately and erodes the future consumable base by the size of the placement not made. The lag is the problem: a placement lost in 2025 costs consumable revenue in every subsequent year of the forecast, so the effect compounds rather than passing.

3. Price deflation from multiplex substitution

A syndromic panel carrying twenty targets replaces six to eight single-target assays. The panel is priced above any individual assay and is ordered where no single assay would have been ordered, but the price per target falls sharply and the single-target reagent lines lose volume. Transmission channel: revenue per episode declines wherever multiplexing takes hold, and it is only offset if the panel generates volume that did not previously exist. Whether that offset holds is empirical, and the 2025 evidence is mixed: panel businesses grew volume at double-digit rates in several portfolios while aggregate reagent pricing fell. A forecast that counts multiplex volume growth without allowing for the price-per-target decline will overstate revenue.

4. Respiratory seasonality and demand concentration

Cepheid’s respiratory revenue was approximately USD 500 million in the fourth quarter of 2025 alone. That is roughly a quarter of Cepheid’s annualised PCR revenue arriving in one season, and it means a material share of the closed-cartridge layer’s revenue is a function of how long and how severe a winter turns out to be. Transmission channel: a mild season reduces revenue without reducing the instrument installed base, the manufacturing footprint or the service organisation that support it, so operating leverage works in reverse. The manufacturing capacity for these consumables was built at pandemic scale and is not fully absorbed, which makes the fixed-cost base larger than the seasonal demand would justify.

5. Digital PCR capex deferral against a public target

QIAGEN has committed publicly to USD 250 million of digital PCR revenue by 2028, a figure that would represent 27.4% of a segment reaching USD 912 million at 15% growth, against roughly 14.8% today. Transmission channel: the target depends on placements compounding at a rate the capital-spending environment has already interrupted once. If placements stall, the consumable annuity that the target depends on arrives late, and the shortfall lands entirely on the fastest-growing part of the market. Because digital PCR contributes 0.95 of the 5.00 percentage points, a halving of its growth rate removes roughly half a point from the market rate – material, but not fatal, which is itself an important finding about how little of this forecast depends on the segment everyone discusses.

6. Reimbursement and coverage determination

A test that is cleared but not covered has no commercial pathway in a reimbursed market. The American fee schedule caps increases for clinical laboratory tests at 15% a year across 2027 to 2029, which limits how much a new PCR assay can be paid for even when it replaces a more expensive pathway. Transmission channel: coverage determines whether a cleared assay generates revenue at all, and the fee schedule determines how much. Neither is a function of analytical performance or clinical utility in the way that suppliers describe. The mitigation available to a supplier is menu breadth across indications that are already covered, which is precisely the strategy the tier-one set is pursuing.

7. Substitution at both ends of the technology curve

PCR is being squeezed from above and below. Above, next-generation sequencing takes high-multiplex and tumour-profiling applications where a broad panel of variants is required; the NGS report in this cluster documents a market growing faster than this one. Below, isothermal amplification and clustered-regularly-interspaced-short-palindromic-repeats chemistry take low-complexity point-of-care questions where a thermocycler is a liability. Transmission channel: PCR retains the middle – moderate multiplex, moderate throughput, quantitative and well-understood – and the middle is where volume is largest and price is weakest. The risk is not that PCR is displaced; it is that PCR becomes the cheap layer of a market whose value has moved to the layers on either side.

8. Buyer concentration and tender power

Laboratory networks have consolidated faster than their suppliers. Transmission channel: a consolidated buyer negotiates on price across an entire menu, and it can credibilise a threat to build assays internally because it already employs the scientists to do it. The laboratory-developed test framework that survived its 2025 challenge is the institutional basis of that threat, and it caps the price of any assay a competent laboratory could reproduce. The larger the buyer, the closer the price falls to the laboratory’s own cost.

The risks that arrive together

Two pairs are correlated, and a forecast that treats them as independent understates the tail.

China repricing and funding constraint are both fiscal, so they tighten in the same years rather than offsetting each other. Both appeared in 2025 simultaneously, which is why the base year is a trough and not a trend.

Respiratory season severity and buyer concentration are both negotiating variables, and they arrive in the same procurement cycle. A mild season raises the buyer’s incentive to extract price, because the buyer’s own volume has fallen and its fixed costs have not.

The sensitivity

The number that matters is what the remaining years must deliver if the first year disappoints. If the 2025 base contracts a further 2% in 2026 before recovery begins, the remaining seven years must compound at 6.0448% to arrive at USD 15.40 billion in 2033 – more than a full percentage point above the headline rate and above the guidance of either participant that publishes a forward number. That is the honest shape of the risk: a forecast of 5.00% carries roughly one point of hidden acceleration if the trough deepens before it turns.

The upside case is not digital PCR, which is too small to move the aggregate. It is the reversal of the three base-year drags in sequence: China prices finding a floor rather than continuing to reset, academic capital budgets returning to growth, and the last of the COVID comparison leaving the base. If all three occur, the market’s underlying growth rate is closer to the disclosed underlying rates of its best-performing franchises – Roche’s Molecular Lab at 4% CER and Hologic’s molecular business at 4.5% constant currency excluding COVID – plus the digital PCR contribution, which is where a 6% to 7% outcome becomes arithmetically possible.

Regulatory Landscape

Regulatory and Policy Environment

Two regulatory variables determine the revenue of a PCR product, and neither of them is analytical performance. The first is which authorisation route the product travels, because that determines how long it may be sold. The second is whether a laboratory may build the same test itself, because that determines what the supplier may charge.

Two American routes of very different duration

A 510(k) clearance or a de novo classification produces a marketing authorisation that persists, with a defined intended use, a label and a stable commercial life. An Emergency Use Authorization under Section 564 produces a permission that exists only for the duration of the declaration justifying it, and it can be terminated or revoked before the commercial cycle completes.

The distinction shaped the PCR market more than any other rule over the last six years. A large share of the assays developed for SARS-CoV-2 and for each subsequent respiratory pathogen reached the market through the emergency route, and their revenue existed under the same condition as their authorisation. The consequence for this forecast is direct and is built into the base year: the 2025 base excludes residual COVID-19 assay revenue, not because it disappeared entirely but because it is a policy-dependent revenue line rather than a commercial one. Abbott still recorded USD 297 million of COVID-19 testing-related sales in 2025, against USD 747 million in 2024, and that residue is excluded from this report’s perimeter.

The second consequence is commercial rather than financial. A product authorised for a narrow intended use cannot be marketed for a broader one, however capable the underlying multiplex chemistry. The menu a supplier actually owns is the menu it has been cleared for, which is why a twenty-target panel and a twelve-target panel can be the same instrument and a different business.

CLIA categorisation sets the setting of use

The Clinical Laboratory Improvement Amendments determine where a test may be performed and by whom, and for a PCR product the CLIA categorisation is as commercially decisive as its clinical performance. A test categorised as moderately or highly complex may only be run in a laboratory holding the corresponding certificate, which confines the product to the central laboratory channel. A waived test may be performed by personnel without formal laboratory training in a waived setting, which opens physician offices, pharmacies and, where the labelling permits, the home.

The commercial difference is several multiples of addressable market for an identical assay, and it has nothing to do with how well the test amplifies. Waiver is obtained by demonstrating that the test is simple and that its errors are inconsequential in untrained hands, which is an argument about device design and result interpretation rather than about molecular sensitivity. That is why so much point-of-care PCR development is engineering work on the cartridge and the reader rather than chemistry work on the assay.

The laboratory-developed test sequence, and why it sets the price ceiling

The most consequential regulatory sequence in this market was not about a test at all.

On 6 May 2024 the FDA issued a final rule amending the definition of in vitro diagnostic products in 21 CFR 809.3(a) to add the words including when the manufacturer of these products is a laboratory, which would have subjected laboratory-developed tests to the device framework. On 31 March 2025 a United States district court vacated that rule. On 19 September 2025 the FDA issued a final rule reverting to the text of the regulation as it stood before the 2024 amendment took effect.

For PCR suppliers the outcome is double-edged and should be read carefully. Had the rule survived, every laboratory-developed molecular panel would have required device authorisation, and the menu layer would have belonged to companies with cleared products – a transfer of value towards the supplier. The vacatur preserved the laboratories’ ability to build their own assays, which means the largest customers for PCR reagents are also potential competitors for the assay, and the price of an assay is capped at what a reference laboratory could reproduce internally.

This is the correct reading of the current position: the laboratory-developed test framework is deflationary for assay pricing in the United States, which supports testing volume and compresses supplier margin. For an open qPCR reagent business, it is the single most important sentence in this chapter, because it means the customer can always substitute its own labour for the supplier’s product.

Digital PCR has a specific dependence on that same framework

Most clinical digital PCR use reached patients through laboratory-developed tests rather than cleared assays. A hospital laboratory validating an absolute copy-number assay for BCR-ABL monitoring on its own platform is running a laboratory-developed test, and the legal basis for doing so is the framework that survived in 2025. Had the 2024 rule stood, a substantial share of clinical digital PCR volume would have required device authorisation, which the segment’s current revenue base could not have supported across the installed base.

This creates a dependency that is easy to miss in a technology discussion: the fastest-growing part of this market is legally dependent on a rule that was vacated rather than never written. A future reversal of that position would slow clinical digital PCR adoption without touching the technology, and it would do so fastest in the applications where the segment’s margin is best.

Europe: classification and the notified body queue

The European In Vitro Diagnostic Regulation replaced the earlier directive with a risk-based classification in which assays detecting transmissible agents, and assays used for blood and tissue compatibility, sit in the highest classes requiring notified body conformity assessment with substantially more analytical and clinical evidence.

Three practical effects follow. Compliance cost per assay rises sharply, which favours participants with a broad menu that can absorb the cost across many products. Notified body capacity, rather than scientific capability, becomes the gate on how quickly a menu can be extended, introducing a queue that does not respond to commercial urgency. And the evidence burden falls hardest on the decentralised, near-patient products where growth is highest, because demonstrating lay-user performance is a different and more expensive exercise than demonstrating laboratory performance.

China: registration is necessary, procurement is binding

China operates a national registration system for in vitro diagnostics alongside provincial and national procurement programmes that set the price at which registered products are bought. The 2025 evidence shows which of the two binds. Roche’s Asia-Pacific diagnostics revenue fell 12% at constant exchange rates to CHF 3,386 million, and its molecular and pathology growth was described as offsetting the impact of healthcare pricing reforms in China – a description of registration and menu succeeding while price failed. Bio-Rad attributed lower reimbursement rates for diabetes testing in China as a partial offset to its Clinical Diagnostics growth.

For PCR specifically, the implication is that authorisation in China is a necessary condition for revenue and not a sufficient one. The price is an administrative variable, and no amount of menu breadth defends it.

Programme procurement and prequalification

Outside the reimbursed markets, a substantial share of PCR testing is purchased by ministries and donor-funded programmes, and access is governed by prequalification and local registration rather than by a marketing authorisation alone. A product that is authorised in Europe but not prequalified cannot be sold into programme procurement; a product prequalified but not registered locally may still be blocked at the border.

The barrier this creates is administrative rather than technical, and it favours incumbents with registration files in many jurisdictions. It also explains why the fastest-growing near-patient platforms invested in registrations early: in programme markets the cost of market access is paid before there is any revenue to justify it, which is a barrier a small competitor cannot easily cross.

What the regulatory position implies for the forecast

Three conclusions bound the 5.00% path.

First, durable revenue is cleared product sold into a covered channel. Emergency-authorised product sold into declaration-driven demand is excluded from the base year, and the forecast does not assume it returns.

Second, the American price ceiling is set by the laboratory-developed test framework, not by competition between suppliers. That is why the 2025 vacatur matters more to this market’s revenue than any individual clearance could.

Third, growth in the emerging markets is determined by registration and prequalification rather than by epidemiology. The markets where PCR volumes will grow fastest are the ones where a supplier has already spent the administrative cost of being permitted to sell, and that spending shows up as a barrier to entry before it shows up as revenue.

Further Reading

Two published analyses examine the parts of this forecast that carry the most weight: the size of the addressable market, and the arithmetic behind the smallest and fastest-growing segment.

• A Vendor’s Addressable Market Is Not the Market – QIAGEN puts the 2025 qPCR addressable market at approximately USD 2.7 billion while Roche’s Molecular Lab alone reported USD 3,048 million. The gap is definitional rather than an error: open chemistry excludes the closed cartridge systems where the largest participants earn their molecular revenue, and a supplier’s addressable market is a sales instrument rather than a measurement.
• Twenty-Seven Point Four Per Cent Is a Plan, Not a Forecast – QIAcuity at USD 89 million against a USD 600 million segment is a 14.8% share. The USD 250 million 2028 target requires 27.4% at 15% segment growth, and more than 30% at 10%, so a dollar target on a growing denominator is a share target in disguise.